Second-line Treatment of Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 23, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Trifluridine/tipiracil

patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).

Trial Locations (1)

250012

RECRUITING

Qilu hospital of Shandong University, Jinan

All Listed Sponsors
collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

Qianfoshan Hospital

OTHER

collaborator

Binzhou People's Hospital

OTHER

collaborator

Binzhou Medical University

OTHER

collaborator

Yantai Yuhuangding Hospital

OTHER

collaborator

Linyi Tumour Hospital

OTHER

lead

Qilu Hospital of Shandong University

OTHER